Tech Transfer: Lilly, Purdue University Work To Optimize Injectable Therapies
Five-year collaboration between the Indiana-based pharma and university also hopes to develop predictive modeling for clinical development success.
You may also be interested in...
Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.